A major focus in urologic research is the identification of new biomarkers with improved specificity for clinically-significant prostate cancer.
A promising new test based on prostate-specific antigen (PSA) is called the Prostate Health Index (PHI), which has recently been approved in the United States, Europe and Australia. PHI is a mathematical formula that combines total PSA, free PSA and (-2)proPSA. Numerous international studies have consistently shown that PHI outperforms its individual components for the prediction of overall and high-grade prostate cancer on biopsy. PHI also predicts the likelihood of progression during active surveillance, providing another noninvasive modality to potentially select and monitor this patient population. This article reviews the evidence on this new blood test with significant promise for both prostate cancer screening and treatment decision-making.
Written by:
Loeb S, Catalona WJ. Are you the author?
Department of Urology and Population Health, New York University and the Manhattan Veterans Affairs Medical Center, New York, NY, USA; Department of Urology, Northwestern Feinberg School of Medicine, Chicago, IL 60611, USA.
Reference: Ther Adv Urol. 2014 Apr;6(2):74-77.
doi: 10.1177/1756287213513488
PubMed Abstract
PMID: 24688603
UroToday.com Prostate Cancer Section
